Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, LH/POB 232, Boston, MA 02114, USA.
Ther Adv Med Oncol. 2013 Jan;5(1):41-50. doi: 10.1177/1758834012458480.
Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during the past few years. While there is early evidence of antitumor activity of several agents in phase I/II studies, phase III efforts with a few targeted agents have failed, highlighting the challenges of new drug development in HCC. This review summarizes the current status of other molecularly targeted agents under development in advanced HCC.
尽管索拉非尼已成功获得批准并广泛应用，但晚期肝细胞癌（HCC）患者的预后仍然较差。幸运的是，在过去几年中，人们对开发其他 HCC 分子靶向药物重新产生了浓厚兴趣，并积极开展研究。虽然在 I/II 期研究中，有几种药物具有早期抗肿瘤活性的证据，但少数靶向药物的 III 期研究未能取得成功，突显了 HCC 新药开发的挑战。本文综述了晚期 HCC 中正在开发的其他分子靶向药物的现状。
